Chemotherapy-induced peripheral neuropathy (CIPN) is a major challenge, with increasing
impact as oncological treatments, using potentially neurotoxic chemotherapy, improve …

Oxaliplatin (OHP)-induced peripheral neurotoxicity (OIPN) is a severe clinical problem and
potentially permanent side effect of cancer treatment. For the management of OIPN, accurate …

Abstract Recently updated American Society of Clinical Oncology (ASCO) guidelines for
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy (CIPN) in …

Taxane‐induced peripheral neurotoxicity (TIPN) is the most common non‐hematological
side effect of taxane‐based chemotherapy, and may result in dose reductions and …

Chemotherapy-induced peripheral neurotoxicity (CIPN) is a major dose-limiting side effect of
many anti-cancer agents, including taxanes, platinums, vinca alkaloids, proteasome …

Paclitaxel-induced peripheral neuropathy (PIPN) is a barrier to effective cancer treatment
and impacts quality of life among patients with cancer. We used a translational approach to …

Chemotherapy-induced peripheral neuropathy is one of the most frequent dose-limiting side
effects, observed in patients receiving antineoplastic agents, persisting for up to two years …

Paclitaxel‐induced peripheral neuropathy (PIPN) is a common and dose‐limiting adverse
event. The role of P‐glycoprotein (P‐gp) in the neuronal efflux of paclitaxel was assessed …

Objective Chemotherapy-induced peripheral neuropathy (CIPN) is a common and severe
adverse reaction in taxane-based chemotherapy. This study aimed to analyze the risk …

The nervous system governs both ontogeny and oncology. Foundational discoveries have
clarified the direct communication of neurotransmitters with tumors and indirect interactions …